Antares Pharma Cmn (ATRS) 1.26 $ATRS LabCorp Q2 Results

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2016 at 1:02 AM

Antares Pharma Cmn (ATRS) 1.26 $ATRS

LabCorp Q2 Results Strong, Sequenom Buyout Raises Hope
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 10:16AM CDT
On Aug 18, 2016, we issued an updated research report on LabCorp (LH), a leading independent clinical laboratory company.
DSCI: 4.72 (-0.12), ALGN: 95.78 (+2.02), LH: 137.71 (+1.58), ATRS: 1.26 (+0.05)

Antares Pharma Reports Second Quarter 2016 Operating and Financial Results
GlobeNewswire - Tue Aug 09, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today reported operating and financial results for the second quarter ended June 30, 2016. The Company reported revenue of $12.2 million and a net loss per share of $0.04 for the second quarter and revenue of $24.5 million and a net loss of $0.09 per share for the first half of 2016. Product sales, which represent sales of our proprietary products and devices or device components to our partners, rose to $8.7 million for the three months ended June 30, an increase of 49% compared to the second quarter of 2015.
ATRS: 1.26 (+0.05)

Antares Pharma to Report Second Quarter Financial and Operating Results and Host Webcast and Conference Call
GlobeNewswire - Tue Aug 02, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its second quarter 2016 financial results and recent operating progress before the market opens on Tuesday, August 9, 2016. Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 9, 2016 to discuss the results.
ATRS: 1.26 (+0.05)

What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet
PR Newswire - Fri Jun 24, 6:49AM CDT
Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on Stock-Callers.com belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:
PODD: 43.12 (+0.66), GMED: 23.97 (+0.51), NUVA: 66.74 (+0.68), ATRS: 1.26 (+0.05)

Antares Pharma Announces Settlement of Patent Litigation for Key Alliance Business Product
GlobeNewswire - Thu Jun 23, 9:54AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Teva Pharmaceuticals USA, Inc. has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC (AstraZeneca) relating to AstraZeneca's US Patent Nos. 6,858,576, 6,872,700, 6,956,026, 7,297,761, 6,902,744, 7,521,423, and 7,741,269 and AstraZeneca's BYETTA (exenatide), and entered into a settlement and license agreement with AstraZeneca, pursuant to which AstraZeneca granted a license to Teva to manufacture and commercialize the generic version of BYETTA described in Teva's ANDA No. 205984 in the United States.
ATRS: 1.26 (+0.05)

Medical Device Leader Series: Top Needle-Free Injection Device Developers, Manufacturers and Marketers in 2016
PR Newswire Europe - Tue Jun 21, 8:02AM CDT
LONDON, June 21, 2016 /PRNewswire/ --
ATRS: 1.26 (+0.05)

Antares Pharma to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Wed Jun 01, 8:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 4:30 p.m. Eastern Time.
ATRS: 1.26 (+0.05)

Antares Pharma Announces Update to QuickShot Testosterone Clinical Program
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the last patient has completed treatment in a dose-blinded, multiple-dose, concentration controlled 26-week safety and pharmacokinetic phase 3 study of QuickShot(R) Testosterone (QS T) administered subcutaneously once each week to adult males with hypogonadism. The study, QST-15-005 included a screening phase, a titration phase and a treatment phase for evaluation of safety and tolerability assessments, including laboratory assessments, adverse events and injection site assessments. The study was conducted to help ensure that we satisfy the U.S. Food and Drug Administration's recommendation that we have a safety database of approximately 350 subjects exposed to QS T in total with approximately 200 subjects exposed for six months and approximately 100 subjects exposed for a year.
ATRS: 1.26 (+0.05)

Antares Pharma reports 1Q loss
Automated Insights - Mon May 09, 6:08AM CDT
EWING, N.J. (AP) _ Antares Pharma Inc. (ATRS) on Monday reported a loss of $7.7 million in its first quarter.
ATRS: 1.26 (+0.05)

Antares Pharma To Host First Quarter Operating And Financial Results Conference Call
GlobeNewswire - Mon May 02, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced it will release its first quarter 2016 financial results and recent operating progress before the market opens on Monday, May 9, 2016, and host a conference call shortly thereafter at 8:30 a.m. ET (Eastern Time) to discuss the results. Robert F. Apple, President and Chief Executive Officer will host the call.
ATRS: 1.26 (+0.05)

New Strong Sell Stocks for April 28th
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
CAVM: 56.28 (-0.43), CMG: 408.41 (-6.27), SAM: 186.06 (+3.86), DOV: 72.75 (+0.21), ATRS: 1.26 (+0.05)

Antares Pharma to Present at the Deutsche Bank Securities, Inc. 41st Annual Health Care Conference
GlobeNewswire - Wed Apr 27, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert Apple, President and Chief Executive Officer, will present at the Deutsche Bank Securities, Inc. 41 Annual Health Care Conference on Wednesday May 4, 2016 at 9:20 am Eastern Time.
DB: 14.90 (+0.21), ATRS: 1.26 (+0.05)

OTREXUP.COM Website Awarded a Bronze Horizon Interactive Award
GlobeNewswire - Mon Apr 25, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the Company's OTREXUP.COM website has been awarded a 2015 Bronze Horizon Interactive Award in the category of Consumer Information Websites. The Horizon Interactive Awards are among the most prestigious awards in the field of interactive and creative media. The annual international competition, now in its 14 season, recognizes, promotes and awards the best web sites, videos, online advertising, print media and mobile applications. In 2015 alone, Horizon received over 1,100 competition submissions from more than 40 countries. A volunteer panel of industry professionals review the entries to determine the recognition and shed a spotlight on the winners and the people who made it happen.
ATRS: 1.26 (+0.05)

4 Trending Small Cap Stocks Making Big Moves Today
ACCESSWIRE - Fri Apr 22, 9:12AM CDT
NEW YORK, NY / ACCESSWIRE / April 22, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. EBIO, EXXI, SUNE and ATRS are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
EXXI: 0.13 (-0.01), EBIO: 4.84 (-0.05), SUNE: 0.34 (unch), ATRS: 1.26 (+0.05)

Antares Pharma Discloses "Pen 1" Development Project as Teriparatide
GlobeNewswire - Tue Apr 05, 6:00AM CDT
Antares Pharma, Inc. (NASDAQ:ATRS) today disclosed that the "Pen 1" development project with Teva Pharmaceutical Industries, Ltd. (Teva) relates to a generic form of Forteo (teriparatide [rDNA origin] injection) (Teriparatide), marketed by Eli Lilly and Company (Lilly). Forteo is an injectable treatment for osteoporosis in postmenopausal women and men at high risk for fracture and for glucocorticoid induced osteoporosis in men and postmenopausal women. On March 16, 2016 Lilly filed a lawsuit against Teva in response to Teva's Paragraph IV notice and filing contained in their Abbreviated New Drug Application (ANDA) for Teriparatide filed with, and accepted by, the U.S. Food and Drug Administration (FDA). Based on available information, Antares believes that Teva may be the "first applicant" to file an ANDA for a generic equivalent of Forteo and, should Teva's ANDA be approved, may be entitled to 180 days of generic market exclusivity.
ATRS: 1.26 (+0.05)

New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 65.64 (+0.92), ALIM: 1.50 (-0.05), AMD: 7.51 (+0.16), CWT: 31.04 (+0.70), ATRS: 1.26 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...